Switch theme
Sign up to access all valuation multiples
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.
2006
n/a
LTM Revenue $5.3M
LTM EBITDA -$3.4M
$173M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Orthocell has a last 12-month revenue (LTM) of $5.3M and a last 12-month EBITDA of -$3.4M.
In the most recent fiscal year, Orthocell achieved revenue of $3.4M and an EBITDA of -$7.5M.
Orthocell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Orthocell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.3M | XXX | $3.4M | XXX | XXX | XXX |
| Gross Profit | $4.0M | XXX | $2.4M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | -$3.4M | XXX | -$7.5M | XXX | XXX | XXX |
| EBITDA Margin | -64% | XXX | -220% | XXX | XXX | XXX |
| EBIT | -$3.9M | XXX | -$7.8M | XXX | XXX | XXX |
| EBIT Margin | -73% | XXX | -229% | XXX | XXX | XXX |
| Net Profit | -$3.9M | XXX | -$4.6M | XXX | XXX | XXX |
| Net Margin | -73% | XXX | -135% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Orthocell's stock price is AUD 1 (or $1).
Orthocell has current market cap of AUD 300M (or $193M), and EV of AUD 270M (or $173M).
See Orthocell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $173M | $193M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Orthocell has market cap of $193M and EV of $173M.
Orthocell's trades at 38.2x EV/Revenue multiple, and -32.0x EV/EBITDA.
Equity research analysts estimate Orthocell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Orthocell has a P/E ratio of -49.2x.
See valuation multiples for Orthocell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $193M | XXX | $193M | XXX | XXX | XXX |
| EV (current) | $173M | XXX | $173M | XXX | XXX | XXX |
| EV/Revenue | 32.4x | XXX | 38.2x | XXX | XXX | XXX |
| EV/EBITDA | -50.7x | XXX | -32.0x | XXX | XXX | XXX |
| EV/EBIT | -44.2x | XXX | -29.7x | XXX | XXX | XXX |
| EV/Gross Profit | 43.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -49.2x | XXX | -45.5x | XXX | XXX | XXX |
| EV/FCF | -28.3x | XXX | -31.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrthocell's last 12 month revenue growth is 65%
Orthocell's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Orthocell's rule of 40 is -165% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Orthocell's rule of X is 99% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Orthocell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 65% | XXX | 63% | XXX | XXX | XXX |
| EBITDA Margin | -64% | XXX | -120% | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -165% | XXX | -54% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 99% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 163% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 299% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Orthocell acquired XXX companies to date.
Last acquisition by Orthocell was XXXXXXXX, XXXXX XXXXX XXXXXX . Orthocell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Orthocell founded? | Orthocell was founded in 2006. |
| Where is Orthocell headquartered? | Orthocell is headquartered in Australia. |
| Is Orthocell publicy listed? | Yes, Orthocell is a public company listed on ASX. |
| What is the stock symbol of Orthocell? | Orthocell trades under OCC ticker. |
| When did Orthocell go public? | Orthocell went public in 2014. |
| Who are competitors of Orthocell? | Similar companies to Orthocell include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Orthocell? | Orthocell's current market cap is $193M |
| What is the current revenue of Orthocell? | Orthocell's last 12 months revenue is $5.3M. |
| What is the current revenue growth of Orthocell? | Orthocell revenue growth (NTM/LTM) is 65%. |
| What is the current EV/Revenue multiple of Orthocell? | Current revenue multiple of Orthocell is 32.4x. |
| Is Orthocell profitable? | Yes, Orthocell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Orthocell? | Orthocell's last 12 months EBITDA is -$3.4M. |
| What is Orthocell's EBITDA margin? | Orthocell's last 12 months EBITDA margin is -64%. |
| What is the current EV/EBITDA multiple of Orthocell? | Current EBITDA multiple of Orthocell is -50.7x. |
| What is the current FCF of Orthocell? | Orthocell's last 12 months FCF is -$6.1M. |
| What is Orthocell's FCF margin? | Orthocell's last 12 months FCF margin is -115%. |
| What is the current EV/FCF multiple of Orthocell? | Current FCF multiple of Orthocell is -28.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
